Compare DexCom, Inc. (DXCM) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nu Holdings Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Nu Holdings Ltd trades at $16.12 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 2.3× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nu Holdings Ltd for 53 Days on average.
| DXCM | NU | |
|---|---|---|
Market Cap | $31.86B | $74.30B |
Volume | 3,607,070 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $92.34 | $18.76 |
52-Week Low | $54.84 | $11.60 |
Typical Hold Time | 62 Days | 53 Days |
Enterprise Value | $31.32B | $96.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
NU Holdings Ltd. (NU) is trading at $15.38, down 1.28% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company demonstrates strong fundamental growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent news highlights market volatility around acquisition speculation, but the core business in Brazilian digital banking remains robust.
The outlook for NU is positive, supported by rapid customer growth and expanding profitability, though risks include credit concentration and integration challenges from potential acquisitions. Analyst consensus is bullish with a $16.53 price target, suggesting potential upside from the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
